with some patients surviving decades without requiring therapy while others have more aggressive disease requiring immediate treatment and associated with a shortened survival. Conventional treatment has relied on alkylating agents such as chlorambucil and, more recently, purine analogues such as a fludarabine. As single agents these therapies achieve good overall response (OR) rates of up to 80%, but complete remission (CR) rates of <10% for chlorambucil and 15-20% for single-agent fludarabine. Combinations of these drugs, such as fludarabine together with cyclophosphamide, have shown an increase in CR rates up to 40% with a prolongation of progression-free survival (PFS). However, none of the randomised studies has shown any survival advantage. This latter observation is largely due to the ability to successfully re-treat relapsed patients. However, patients who become refractory to alkylator-and fludarabine-based treatments have traditionally had a poor response (<20%) to salvage therapy and a greatly shortened survival (median 10 months). 1 Over the past decade this bleak situation for patients has been improved by the introduction of novel agents, including monoclonal antibodies. Alemtuzumab is a fully humanised monoclonal antibody directed against the CD52 antigen, which is widely expressed on B and T lymphocytes. It is licensed for the treatment of fludarabine refractory CLL and has been shown to induce remissions in 33-53% of patients in this setting. 2, 3 The standard dosing schedule is 30mg given three times a week intravenously for 12 weeks.
Alemtuzumab Monotherapy
The first report of the use of alemtuzumab as front-line therapy was in 1996 by Osterborg et al. 4 Nine patients received the standard treatment, although in four patients the antibody was administered subcutaneously, and therapy was continued in all patients up to 18 weeks. The OR rate was 89% with three patients achieving CR. This group expanded the patient cohort and reported a further 41 patients treated with subcutaneous alemtuzumab as first-line therapy for a total of 18 weeks. 5 The OR rate was maintained at 81% in 38 evaluable patients. Nineteen per cent of patients achieved CR and 68% a partial remission (PR). At the time of publication in 2002 the time to treatment failure had not been reached at 18+ months. These results are comparable to those observed for single-agent fludarabine 6 and superior to those for single-agent rituximab 7 (see Table 1 ). Interestingly, complete responders required 18 weeks of therapy to achieve their best response, with significant improvement in bone marrow clearance between the 12-and 18-week evaluation points. Furthermore, patients with low-volume lymphadenopathy also achieved complete remissions in contrast to the observation in relapsed refractory patients that lymphadenopathy cycles. Response rates assessed by an independent panel showed OR of 83% for alemtuzumab compared with 55% for chlorambucil with CR rates of 24% and 2%, respectively (see Table 1 ). This translated into improved PFS for the patients who received alemtuzumab, with a 43% lower risk of progression or death. Notably, in patients who had the cytogenetic deletion of 17p (p53), there was a three-fold increase in OR with alemtuzumab (64%) compared with chlorambucil (26%).
Statistically significant superior responses were also seen for patients 
Alemtuzumab as First-line Treatment for Progressive B-cell Chronic Lymphocytic Leukaemia with deletion 13q and deletion 11q treated with alemtuzumab compared with chlorambucil. Infections, including CMV, were reported in 76% of patients receiving alemtuzumab compared with 50% of chlorambucil patients while on study. Grade 3 and 4 lymphopaenia and neutropaenia were more common with alemtuzumab, but anaemia and thrombocytopenia were similar in the two treatment groups. Episodes of bacterial sepsis and febrile neutropaenia were comparable and the increase in infection in the alemtuzumab arm was almost entirely attributable to CMV reactivation. Although CMV reactivation occurred in half the patients, it was only symptomatic in 16%. This toxicity was therefore manageable by screening and pre-emptive treatment. Grade 3 or 4 infusion-related events were seen in 13% of patients receiving alemtuzumab and these were largely confined to the first few weeks of therapy. In contrast, adverse events increased over time in the chlorambucil arm where the median duration of treatment was twice as long. The toxicity profile of alemtuzumab in previously untreated patients appears to be much more acceptable with no increased treatment-related mortality compared with chlorambucil in the CAM307 randomised study. The Lundin study showed that efficacy for 18 weeks of subcutaneous alemtuzumab was equivalent to 12 weeks of intravenous therapy. Since subcutaneous administration results in fewer infusion-related side effects, this may be the preferable route.
Alemtuzumab Consolidation Therapy
Studies of alemtuzumab treatment of CLL, particularly in the relapsed/refractory setting, have consistently shown that patients with bulky nodal disease are less likely to respond to treatment compared with those patients who have low volume or no lymph node enlargement. This is in contrast to the excellent clearance of disease from the blood and bone marrow. In addition, in the Moreton study 3 patients who achieved complete remissions and who were also negative for minimal residual disease (MRD) using a sensitive four-colour flow cytometry 9 had significantly prolonged PFS and overall survival (OS). Several studies, using a variety of treatment regimens, have confirmed the observation that those patients achieving MRD-negativity have prolonged remissions compared with those patients who are MRD-positive at the end of therapy. [10] [11] [12] These observations have provided a rationale for using alemtuzumab as consolidation of remissions achieved using fludarabinebased induction regimens. Four groups have published their results for this strategy using various treatment schedules, doses and routes of administration (see Table 2 ). [13] [14] [15] [16] Although not comparable, all have demonstrated the efficacy of such an approach in improving responses in around 50% of patients receiving consolidation. There has only been one randomised study which was reported by the German study group in Consolidation after first induction treatment of CLL is therefore feasible and can deepen remission and increase PFS in a proportion of patients.
However, there is a risk of toxicity and there are also financial implications. It may therefore be prudent to reserve this strategy for those patients with higher risk disease. Furthermore, a larger randomised study needs to be completed in such a group to confirm safety and efficacy as well as establishing the optimal timing, dose and delivery (intravenous or subcutaneous).
Alemtuzumab for High-risk Chronic Lymphocytic Leukaemia
It is well recognised that patients who have deletions of chromosome 17p resulting in dysfunction of the p53 pathway have resistance to conventional chemotherapy such as alkylating agents or purine 16 after F
CR = complete response; F = fludarabine; IV = intravenous; OR = overall response; PFS = progression-free survival; SC = subcutaneous; TIW = three times a week.
Several studies, using a variety of 
Conclusion
There have been major advances in the management of CLL over the past decade. This includes the ability to stratify patients according to biological risk parameters such as genetic abnormalities, the introduction of novel therapies such as monoclonal antibodies and the ability to achieve a high proportion of good remissions, including eradication of minimal residual disease. All these strategies have resulted in improved selection of patients for appropriate therapy and better PFS.
Alemtuzumab has been shown to be an effective monotherapy in both first-line and refractory CLL and it is now clear from several studies that toxicity is much reduced and more manageable when alemtuzumab is used earlier in therapy. More data are now needed on the use of alemtuzumab in front-line combination regimens. The most compelling data for alemtuzumab efficacy are in the high-risk cytogenetic group exhibiting p53 deletion when used either as a single agent or in combination with high-dose steroids. In addition, this antibody therapy has been shown to be effective in eradicating residual disease after completion of induction therapy, although the optimal regimen (dose, schedule and route of administration) is still to be determined. ■ 
